While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

There are currently no treatments available for celiac disease beyond a gluten-free diet. Several late-phase companies aim to ...

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...